POST Online Media Lite Edition



 

Roche again extends $4.3 billion Spark offer until December 16

Christian Fernsby |
Roche again extended its offer for shares of gene therapy specialist Spark Therapeutics to December 16 as a regulatory review of the $4.3 billion (3.35 billion pounds) transaction drags on.

Article continues below



Topics: ROCHE    SPARK    OFFER   

Roche and Spark Therapeutics, Inc. announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock of Spark for USD 114.50 per share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019.

The offer, which was previously scheduled to expire at 5:00 p.m., New York City time, on Tuesday, December 10, 2019, has been extended until 5:00 p.m., New York City time, on Monday, December 16, 2019, unless it is extended further under the circumstances set forth in the Merger Agreement. All terms and conditions of the Offer shall remain unchanged during the extended period.

The offer was extended to provide additional time for the U.S. Federal Trade Commission and the UK Competition and Markets Authority to complete their previously disclosed reviews of Roche’s pending acquisition of Spark.


What to read next

Roche enters strategic collaboration with Foundation Medicine
Autodesk announces $100 million 3D investment fund
New Zealand rejects Huawei's first 5G bid citing national security risk